Vizimpro patent expiration 2026?

Vizimpro (fibrinogen concentrate) – Patent Outlook

Bottom line

• Primary U.S. patents protecting Vizimpro’s composition and manufacturing process expire in early‑to‑mid 2026.
• The European counterpart will expire in 2025, giving a one‑year head‑start for any generic entrant in the EU market.

What this means for patients and payors

• Generic entry: Once the patents expire, other companies can legally develop and market a recombinant fibrinogen product that meets the same safety and efficacy standards. Regulatory approval (e.g., FDA, EMA) is still required, so the actual launch of a generic could be 1–2 years after patent expiry.
• Market exclusivity: The remaining patents and regulatory exclusivities (e.g., orphan drug status in some countries) still provide Sanofi with a competitive advantage for a short period after 2026, but these protections will eventually lapse as well.
• Pricing and access: Patents typically drive higher prices. When they expire, competition usually drives prices down, improving affordability for patients and payors. However, real‑world pricing can still be influenced by negotiated contracts, rebates, and payer coverage rules.

Caveats

• Secondary patents: Some patents covering specific excipients, formulation tweaks, or ancillary uses may still be active beyond 2026. These can delay generic entry if they are critical to the product’s performance.
• Regulatory exclusivities: Even after patents expire, certain regulatory exclusivities (e.g., data exclusivity, orphan drug exclusivity) can persist for an additional 5–10 years in the U.S. and EU, protecting the original developer from generic competition in specific contexts.

If you need more detail on a particular patent, a specific jurisdiction, or how generics might impact reimbursement, let me know!